- Therma Bright’s (THRM) AcuVid COVID-19 rapid antigen saliva test has detected the Omicron variant
- The variant, discovered last month in South Africa and Botswana, has now spread into 38 countries
- The company is finalizing a clinical performance study toward its application for AcuVid’s emergency use authorization in the U.S.
- Therma Bright is a medical diagnostic and device technology company
- Therma Bright (THRM) is up by 7.89 per cent and is currently trading at $0.41 per share
Therma Bright’s (THRM) AcuVid COVID-19 rapid antigen saliva test has detected the Omicron variant.
The variant was discovered last month in South Africa and Botswana and has now spread into 38 countries, including the U.S., Canada, the U.K. and several European nations. Early data from The W.H.O. suggests Omicron is more contagious than the Delta variant.
The AcuVid saliva test has also detected the original Wuhan SARS-CoV-2 virus, the P.1 and P.2 variants discovered in Brazil, the B.1.1.7 variant discovered in the U.K. and the Delta B.1.617.2 variant discovered in India.
“As our partners finalize our U.S. AcuVid clinical performance study to submit to the U.S. Food and Drug Administration for Emergency Use Authorization,” said Rob Fia, CEO of Therma Bright, “our team is making sure we check off each new EUA guidance, including testing all COVID-19 variants of concern and production capabilities of a minimum of 500,000 tests per week.”
The company is not making any express or implied claims that its test product has the ability to eliminate or cure COVID-19.
Therma Bright is a medical diagnostic and device technology company.
Therma Bright (THRM) is up by 7.89 per cent and is currently trading at $0.41 per share as of 10:11 am EST.